Acquisition Announced Sponsor buyer
Gilead Sciences acquisition of Arcellx
US$7.8bn equity value
Announced 23 Feb 2026 · NASDAQ: ACLX · US$115.00 cash and scrip per share · 68% premium
Advisers
Arcellx
Target
- Financial adviser
- Legal adviser
- Fairness opinion
Parent
Acquirer
- Financial adviser
- Legal adviser
- The information agent for the Offer
- Target
- Arcellx
- Acquirer
- Parent (Gilead Sciences)
- Sponsor
- Gilead Sciences
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Cell Therapy, Oncology
In the league tables
Similar deals
- Eli Lilly and Company acquisition of Kelonia Therapeutics Apr 2026 · US$7bn · Biotech
- AstraZeneca acquisition of AbelZeta's 50% share of China development and commercialisation rights to C-CAR031 Jan 2026 · US$630m · Biotech
- Galera Therapeutics and Obsidian Therapeutics merger Apr 2026 · US$414m · Biotech
- Merck & Co. acquisition of Terns Pharmaceuticals Mar 2026 · US$6.7bn · Biotech
- GSK acquisition of Nuvalent Jun 2026 · US$11bn · Biotech
Sources
- 2026 Centerview Partners: Exclusive financial advisor to Arcellx on its sale to Gilead Sciences centerviewpartners.com
- 23 Feb 2026 Tender offer communication (SC TO-C), Arcellx, Inc. sec.gov
- 23 Feb 2026 Tender offer communication (SC TO-C), Arcellx, Inc. sec.gov
- 23 Feb 2026 Press release (EX-99.1, exhibit), public affairs@gilead.com sec.gov
- 6 Mar 2026 Tender offer statement (SC TO-T), Arcellx, Inc. sec.gov
- 6 Mar 2026 Target response to tender offer (SC 14D9), Arcellx, Inc. sec.gov


